List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1249869/publications.pdf Version: 2024-02-01

	29994	42291
10,882	54	92
citations	h-index	g-index
332	332	10300
docs citations	times ranked	citing authors
	10,882 citations 332 docs citations	10,882 citations54 h-index332 docs citations332 times ranked

#	Article	IF	CITATIONS
1	The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia. American Journal of Surgical Pathology, 2013, 37, 1469-1489.	2.1	922
2	The International Society of Urological Pathology (ISUP) Grading System for Renal Cell Carcinoma and Other Prognostic Parameters. American Journal of Surgical Pathology, 2013, 37, 1490-1504.	2.1	639
3	Promotion of Bladder Cancer Development and Progression by Androgen Receptor Signals. Journal of the National Cancer Institute, 2007, 99, 558-568.	3.0	353
4	Androgen deprivation therapy for prostate cancer: Current status and future prospects. Prostate, 2004, 61, 332-353.	1.2	279
5	From estrogen to androgen receptor: A new pathway for sex hormones in prostate. Proceedings of the United States of America, 1998, 95, 5527-5532.	3.3	236
6	Promotion of agonist activity of antiandrogens by the androgen receptor coactivator, ARA70, in human prostate cancer DU145 cells. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 7379-7384.	3.3	195
7	Expression of androgen and oestrogen receptors and its prognostic significance in urothelial neoplasm of the urinary bladder. BJU International, 2012, 109, 1716-1726.	1.3	187
8	Renal Tumors. American Journal of Surgical Pathology, 2013, 37, 1518-1531.	2.1	154
9	ASC-J9 ameliorates spinal and bulbar muscular atrophy phenotype via degradation of androgen receptor. Nature Medicine, 2007, 13, 348-353.	15.2	147
10	The 2019 Genitourinary Pathology Society (GUPS) White Paper on Contemporary Grading of Prostate Cancer. Archives of Pathology and Laboratory Medicine, 2021, 145, 461-493.	1.2	143
11	Â5-Androstenediol is a natural hormone with androgenic activity in human prostate cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 11083-11088.	3.3	141
12	Nonâ€invasive papillary urothelial neoplasms: The 2004 WHO/ISUP classification system. Pathology International, 2010, 60, 1-8.	0.6	140
13	Radical Prostatectomy Findings in Patients in Whom Active Surveillance of Prostate Cancer Fails. Journal of Urology, 2009, 182, 2274-2279.	0.2	131
14	Infiltrating Macrophages Promote Prostate Tumorigenesis via Modulating Androgen Receptor-Mediated CCL4–STAT3 Signaling. Cancer Research, 2013, 73, 5633-5646.	0.4	125
15	Retinoblastoma, a Tumor Suppressor, Is a Coactivator for the Androgen Receptor in Human Prostate Cancer DU145 Cells. Biochemical and Biophysical Research Communications, 1998, 248, 361-367.	1.0	123
16	ASC-J9 Suppresses Castration-Resistant Prostate Cancer Growth through Degradation of Full-length and Splice Variant Androgen Receptors. Neoplasia, 2012, 14, 74-IN12.	2.3	123
17	Small Endoscopic Biopsies of the Ureter and Renal Pelvis. American Journal of Surgical Pathology, 2009, 33, 1540-1546.	2.1	122
18	Handling and Staging of Renal Cell Carcinoma. American Journal of Surgical Pathology, 2013, 37, 1505-1517.	2.1	118

#	Article	IF	CITATIONS
19	Development of novel thermal sprayed antibacterial coating and evaluation of release properties of silver ions. Journal of Biomedical Materials Research - Part B Applied Biomaterials, 2009, 89B, 456-465.	1.6	116
20	Loss of androgen receptor expression is not associated with pathological stage, grade, gender or outcome in bladder cancer: a large multiâ€institutional study. BJU International, 2011, 108, 24-30.	1.3	111
21	Decreased Tumorigenesis and Mortality from Bladder Cancer in Mice Lacking Urothelial Androgen Receptor. American Journal of Pathology, 2013, 182, 1811-1820.	1.9	104
22	Androgen deprivation therapy prevents bladder cancer recurrence. Oncotarget, 2014, 5, 12665-12674.	0.8	101
23	Androgen Receptor Coregulators in Prostate Cancer. Clinical Cancer Research, 2004, 10, 2208-2219.	3.2	98
24	Retinoblastoma gene mutations in primary human prostate cancer. Prostate, 1995, 27, 314-320.	1.2	97
25	Modulation of androgen receptor transactivation by gelsolin: a newly identified androgen receptor coregulator. Cancer Research, 2003, 63, 4888-94.	0.4	95
26	Dihydrotestosterone upregulates the expression of epidermal growth factor receptor and ERBB2 in androgen receptor-positive bladder cancer cells. Endocrine-Related Cancer, 2011, 18, 451-464.	1.6	94
27	Molecular basis for the antiandrogen withdrawal syndrome. Journal of Cellular Biochemistry, 2004, 91, 3-12.	1.2	85
28	Androgen receptor signals regulate UDPâ€glucuronosyltransferases in the urinary bladder: A potential mechanism of androgenâ€induced bladder carcinogenesis. Molecular Carcinogenesis, 2013, 52, 94-102.	1.3	85
29	Prognostic and therapeutic significance of the flow cytometric nuclear DNA content in non-small cell lung cancer. Cancer, 1990, 65, 1391-1395.	2.0	84
30	ELK1 is up-regulated by androgen in bladder cancer cells and promotes tumor progression. Oncotarget, 2015, 6, 29860-29876.	0.8	83
31	Transgelin Functions as a Suppressor via Inhibition of ARA54-Enhanced Androgen Receptor Transactivation and Prostate Cancer Cell Growth. Molecular Endocrinology, 2007, 21, 343-358.	3.7	76
32	Retinoblastoma gene mutations in primary human bladder cancer. British Journal of Cancer, 1995, 71, 831-835.	2.9	74
33	Impact of Gleason Subtype on Prostate Cancer Detection Using Multiparametric Magnetic Resonance Imaging: Correlation with Final Histopathology. Journal of Urology, 2017, 198, 316-321.	0.2	74
34	Androgen Receptor Signaling in Bladder Cancer. Cancers, 2017, 9, 20.	1.7	73
35	Androgen deprivation therapy for prostate cancer. Expert Opinion on Pharmacotherapy, 2008, 9, 211-228.	0.9	72
36	The Role of the Androgen Receptor in the Development and Progression of Bladder Cancer. Japanese Journal of Clinical Oncology, 2012, 42, 569-577.	0.6	71

#	Article	IF	CITATIONS
37	Hydroxyflutamide may not always be a pure antiandrogen. Lancet, The, 1997, 349, 852-853.	6.3	70
38	A Comprehensive Analysis of Cribriform Morphology on Magnetic Resonance Imaging/Ultrasound Fusion Biopsy Correlated with Radical Prostatectomy Specimens. Journal of Urology, 2018, 199, 106-113.	0.2	70
39	Differential Induction of Androgen Receptor Transactivation by Different Androgen Receptor Coactivators in Human Prostate Cancer DU145 Cells. Endocrine, 1999, 11, 195-202.	2.2	68
40	Contrary Regulation of Bladder Cancer Cell Proliferation and Invasion by Dexamethasone-Mediated Glucocorticoid Receptor Signals. Molecular Cancer Therapeutics, 2012, 11, 2621-2632.	1.9	68
41	c-erbb-2 gene amplification as a prognostic marker in human bladder cancer. Urology, 2000, 55, 679-683.	0.5	67
42	GATA binding protein 3 is down-regulated in bladder cancer yet strong expression is an independent predictor of poor prognosis in invasive tumor. Human Pathology, 2012, 43, 2033-2040.	1.1	67
43	Tissue Prostate-Specific Antigen Facilitates Refractory Prostate Tumor Progression via Enhancing ARA70-Regulated Androgen Receptor Transactivation. Cancer Research, 2008, 68, 7110-7119.	0.4	66
44	Low-Grade Papillary Urothelial Carcinoma of the Urinary Bladder: A Clinicopathologic Analysis of a Post–World Health Organization/International Society of Urological Pathology Classification Cohort From a Single Academic Center. Archives of Pathology and Laboratory Medicine, 2010, 134, 1160-1163	1.2	65
45	Estrogen receptor α in cancer-associated fibroblasts suppresses prostate cancer invasion via modulation of thrombospondin 2 and matrix metalloproteinase 3. Carcinogenesis, 2014, 35, 1301-1309.	1.3	63
46	Estrogen Receptor Alpha Prevents Bladder Cancer Development via INPP4B inhibited Akt Pathway <i>in vitro</i> and <i>in vivo</i> . Oncotarget, 2014, 5, 7917-7935.	0.8	63
47	Androgenic dependence of exophytic tumor growth in a transgenic mouse model of bladder cancer: a role for thrombospondin-1. BMC Urology, 2008, 8, 7.	0.6	62
48	Frozen section assessment in testicular and paratesticular lesions suspicious for malignancy: its role in preventing unnecessary orchiectomy. Human Pathology, 2012, 43, 1514-1519.	1.1	61
49	Inhibition of the Akt, cyclooxygenase-2, and matrix metalloproteinase-9 pathways in combination with androgen deprivation therapy: Potential therapeutic approaches for prostate cancer. Molecular Carcinogenesis, 2005, 44, 1-10.	1.3	60
50	Thymol inhibits bladder cancer cell proliferation via inducing cell cycle arrest and apoptosis. Biochemical and Biophysical Research Communications, 2017, 491, 530-536.	1.0	60
51	Inactivation of androgen receptor coregulator ARA55 inhibits androgen receptor activity and agonist effect of antiandrogens in prostate cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 5124-5129.	3.3	58
52	Entry and Intracellular Growth of <i>Legionella dumoffii</i> in Alveolar Epithelial Cells. American Journal of Respiratory and Critical Care Medicine, 1998, 157, 1967-1974.	2.5	57
53	A Dominant-negative Mutant of Androgen Receptor Coregulator ARA54 Inhibits Androgen Receptor-mediated Prostate Cancer Growth. Journal of Biological Chemistry, 2002, 277, 4609-4617.	1.6	57
54	Androgen activates β-catenin signaling in bladder cancer cells. Endocrine-Related Cancer, 2013, 20, 293-304.	1.6	56

#	Article	IF	CITATIONS
55	Androgen receptor activity modulates responses to cisplatin treatment in bladder cancer. Oncotarget, 2016, 7, 49169-49179.	0.8	56
56	Histopathological and prognostic significance of the expression of sex hormone receptors in bladder cancer: A meta-analysis of immunohistochemical studies. PLoS ONE, 2017, 12, e0174746.	1.1	54
57	First Clinical Experience With Thermal-Sprayed Silver Oxide–Containing Hydroxyapatite Coating Implant. Journal of Arthroplasty, 2016, 31, 1498-1503.	1.5	53
58	Neutrophil-to-lymphocyte ratio predicts prostatic carcinoma in men undergoing needle biopsy. Oncotarget, 2015, 6, 32169-32176.	0.8	53
59	Cyclosporine A and tacrolimus inhibit bladder cancer growth through down-regulation of NFATc1. Oncotarget, 2015, 6, 1582-1593.	0.8	52
60	Epidermal growth factor induces bladder cancer cell proliferation through activation of the androgen receptor. International Journal of Oncology, 2012, 41, 1587-1592.	1.4	51
61	Characterization of urinary extracellular vesicle proteins in muscle-invasive bladder cancer. Oncotarget, 2017, 8, 91199-91208.	0.8	51
62	Alterations of p16 and p14ARF genes and their 9p21 locus in oral squamous cell carcinoma. Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics, 2009, 107, 81-91.	1.6	50
63	Pitfalls in the Use of Smoothelin to Identify Muscularis Propria Invasion by Urothelial Carcinoma. American Journal of Surgical Pathology, 2010, 34, 418-422.	2.1	50
64	Tumor suppressor gene P53 mutations in human prostate cancer. Prostate, 1995, 27, 18-24.	1.2	49
65	Loss of Heterozygosity at the p53, RB, DCC and APC Tumor Suppressor Gene Loci in Human Bladder Cancer. Journal of Urology, 1996, 155, 1444-1447.	0.2	49
66	A pathological reassessment of organ-confined, Gleason score 6 prostatic adenocarcinomas that progress after radical prostatectomy. Human Pathology, 2009, 40, 1693-1698.	1.1	49
67	The Role of Androgen Receptor Signaling in Ovarian Cancer. Cells, 2019, 8, 176.	1.8	49
68	Differential Induction of the Androgen Receptor Transcriptional Activity by Selective Androgen Receptor Coactivators Keio Journal of Medicine, 1999, 48, 87-92.	0.5	48
69	Expression of transforming growth factor-beta 1 in human bladder cancer. Cancer, 1995, 75, 2565-2570.	2.0	47
70	Expression of AR associated protein 55 (ARA55) and androgen receptor in prostate cancer. Prostate, 2003, 56, 280-286.	1.2	47
71	Loss of GATA3 in bladder cancer promotes cell migration and invasion. Cancer Biology and Therapy, 2014, 15, 428-435.	1.5	46
72	Neutrophil-to-lymphocyte ratio is a prognostic marker in bladder cancer patients after radical cystectomy. BMC Cancer, 2016, 16, 185.	1.1	46

#	Article	IF	CITATIONS
73	GATA3 immunohistochemistry in urothelial carcinoma of the upper urinary tract as a urothelial marker and a prognosticator. Human Pathology, 2017, 64, 83-90.	1.1	46
74	Identification of extracellular vesicle-borne periostin as a feature of muscle-invasive bladder cancer. Oncotarget, 2016, 7, 23335-23345.	0.8	45
75	Solitary Fibrous Tumor of the Pancreas: A Case Report. International Journal of Surgical Pathology, 2007, 15, 311-314.	0.4	44
76	Prostate Cancer Cells Increase Androgen Sensitivity by Increase in Nuclear Androgen Receptor and Androgen Receptor Coactivators; A Possible Mechanism of Hormone-Resistance of Prostate Cancer Cells. Cancer Investigation, 2007, 25, 32-37.	0.6	44
77	Utility of uroplakin II expression as a marker of urothelial carcinoma. Human Pathology, 2015, 46, 58-64.	1.1	43
78	Expression of androgen receptor in non-muscle-invasive bladder cancer predicts the preventive effect of androgen deprivation therapy on tumor recurrence. Oncotarget, 2016, 7, 14153-14160.	0.8	43
79	Serum selenium and vitamin E concentrations in families of lung cancer patients. Cancer, 1987, 60, 1159-1162.	2.0	42
80	Smooth Muscle Neoplasms of the Urinary Bladder: A Clinicopathologic Study of 51 Cases. American Journal of Surgical Pathology, 2010, 34, 502-509.	2.1	41
81	Expression of UDP-glucuronosyltransferase 1A in bladder cancer: Association with prognosis and regulation by estrogen. Molecular Carcinogenesis, 2014, 53, 314-324.	1.3	41
82	Role of the androgen receptor in urothelial cancer. Molecular and Cellular Endocrinology, 2018, 465, 73-81.	1.6	41
83	Nuclear Hormone Receptor Signals as New Therapeutic Targets for Urothelial Carcinoma. Current Cancer Drug Targets, 2012, 12, 14-22.	0.8	40
84	Expression of steroid hormone receptors and its prognostic significance in urothelial carcinoma of the upper urinary tract. Cancer Biology and Therapy, 2016, 17, 1188-1196.	1.5	40
85	Reducing the Agonist Activity of Antiandrogens by a Dominant-negative Androgen Receptor Coregulator ARA70 in Prostate Cancer Cells. Journal of Biological Chemistry, 2003, 278, 19619-19626.	1.6	39
86	Identification of Gleason Pattern 5 on Prostatic Needle Core Biopsy. American Journal of Surgical Pathology, 2011, 35, 1706-1711.	2.1	39
87	The role of NFATc1 in prostate cancer progression: Cyclosporine A and tacrolimus inhibit cell proliferation, migration, and invasion. Prostate, 2015, 75, 573-584.	1.2	39
88	Immunohistochemistry of immune checkpoint markers PD-1 and PD-L1 in prostate cancer. Medicine (United States), 2019, 98, e17257.	0.4	38
89	Suppression of Delta 5-androstenediol-induced androgen receptor transactivation by selective steroids in human prostate cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 11173-11177.	3.3	37
90	Paratesticular Fibrous Pseudotumor: A Morphologic and Immunohistochemical Study of 13 Cases. American Journal of Surgical Pathology, 2010, 34, 569-574.	2.1	36

#	Article	IF	CITATIONS
91	Molecular Determination of Infection Source of a Sporadic <i>Legionella</i> Pneumonia Case Associated with a Hot Spring Bath. Microbiology and Immunology, 1997, 41, 197-202.	0.7	35
92	Outcomes and predictive factors of prostate cancer patients with extremely high prostate-specific antigen level. Journal of Cancer Research and Clinical Oncology, 2014, 140, 1413-1419.	1.2	35
93	Silver-Containing Hydroxyapatite Coating Reduces Biofilm Formation by Methicillin-Resistant <i>Staphylococcus aureus</i> In Vitro and In Vivo. BioMed Research International, 2016, 2016, 1-7.	0.9	35
94	Pretreatment neutrophil-to-lymphocyte ratio predicts the prognosis in patients with metastatic prostate cancer. BMC Cancer, 2016, 16, 111.	1.1	35
95	Prostaglandin receptors induce urothelial tumourigenesis as well as bladder cancer progression and cisplatin resistance presumably via modulating PTEN expression. British Journal of Cancer, 2018, 118, 213-223.	2.9	35
96	Compound A Inhibits Bladder Cancer Growth Predominantly via Glucocorticoid Receptor Transrepression. Molecular Endocrinology, 2015, 29, 1486-1497.	3.7	34
97	Prevention of bacterial adhesion and biofilm formation on a vitamin E-blended, cross-linked polyethylene surface with a poly(2-methacryloyloxyethyl phosphorylcholine) layer. Acta Biomaterialia, 2015, 24, 24-34.	4.1	34
98	Serum chemokine (CC motif) ligand 2 level as a diagnostic, predictive, and prognostic biomarker for prostate cancer. Oncotarget, 2016, 7, 8389-8398.	0.8	34
99	Enzalutamide inhibits androgen receptor–positive bladder cancer cell growth. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 432.e15-432.e23.	0.8	33
100	Nuclear Factor-κB Promotes Urothelial Tumorigenesis and Cancer Progression via Cooperation with Androgen Receptor Signaling. Molecular Cancer Therapeutics, 2018, 17, 1303-1314.	1.9	33
101	Estrogen receptor α promotes lung cancer cell invasion via increase of and crossâ€ŧalk with infiltrated macrophages through the CCL2/CCR2/MMP9 and CXCL12/CXCR4 signaling pathways. Molecular Oncology, 2020, 14, 1779-1799.	2.1	33
102	DNA polymerase \hat{I}^2 gene mutations in human bladder cancer. , 1996, 15, 38-43.		32
103	Reduced Glucocorticoid Receptor Expression Predicts Bladder Tumor Recurrence and Progression. American Journal of Clinical Pathology, 2014, 142, 157-164.	0.4	31
104	Rb+ influx in response to changes in energy generation: Effect of the regulation of the ATP content of HELa cells. Journal of Cellular Physiology, 1984, 119, 273-282.	2.0	30
105	Differential regulation of bladder cancer growth by various glucocorticoids: corticosterone and prednisone inhibit cell invasion without promoting cell proliferation or reducing cisplatin cytotoxicity. Cancer Chemotherapy and Pharmacology, 2014, 74, 249-255.	1.1	29
106	Historical and contemporary perspectives on cribriform morphology in prostate cancer. Nature Reviews Urology, 2018, 15, 475-482.	1.9	28
107	GATA3 in the urinary bladder: suppression of neoplastic transformation and down-regulation by androgens. American Journal of Cancer Research, 2014, 4, 461-73.	1.4	28
108	Expression of semenogelins I and II and its prognostic significance in human prostate cancer. Prostate, 2011, 71, 1108-1114.	1.2	27

#	Article	IF	CITATIONS
109	Silver oxideâ€containing hydroxyapatite coating supports osteoblast function and enhances implant anchorage strength in rat femur. Journal of Orthopaedic Research, 2015, 33, 1391-1397.	1.2	27
110	Cyclosporine A and tacrolimus inhibit urothelial tumorigenesis. Molecular Carcinogenesis, 2016, 55, 161-169.	1.3	27
111	Perineural invasion by prostate cancer on MR/US fusion targeted biopsy is associated with extraprostatic extension and early biochemical recurrence after radical prostatectomy. Human Pathology, 2017, 66, 206-211.	1.1	27
112	The Loss of Retinoblastoma Gene in Association with c-myc and Transforming Growth Factor-beta 1 Gene Expression in Human Bladder Cancer. Journal of Urology, 1995, 154, 371-374.	0.2	26
113	Higher Expression of Peroxisome Proliferator-activated Receptor Î ³ or Its Activation byÂAgonist Thiazolidinedione-rosiglitazone Promotes Bladder Cancer CellÂMigration andÂInvasion. Urology, 2013, 81, 1109.e1-1109.e6.	0.5	26
114	TR4 nuclear receptor functions as a tumor suppressor for prostate tumorigenesis via modulation of DNA damage/repair system. Carcinogenesis, 2014, 35, 1399-1406.	1.3	26
115	ZKSCAN3 promotes bladder cancer cell proliferation, migration, and invasion. Oncotarget, 2016, 7, 53599-53610.	0.8	26
116	Role of frozen section analysis of surgical margins during robot-assisted laparoscopic radical prostatectomy: a 2608-case experience. Human Pathology, 2013, 44, 1556-1562.	1.1	25
117	Androgen receptor activation: a prospective therapeutic target for bladder cancer?. Expert Opinion on Therapeutic Targets, 2017, 21, 249-257.	1.5	25
118	Association ofLpsgene with natural resistance of mouse macrophages againstLegionella pneumophila. FEMS Microbiology Letters, 1991, 89, 51-56.	0.7	24
119	C19-Steroids as androgen receptor modulators: Design, discovery, and structure-activity relationship of new steroidal androgen receptor antagonists. Bioorganic and Medicinal Chemistry, 2006, 14, 5933-5947.	1.4	24
120	Seminal plasma proteins in prostatic carcinoma: increased nuclear semenogelin I expression is a predictor of biochemical recurrence after radical prostatectomy. Human Pathology, 2012, 43, 1991-2000.	1.1	24
121	ATF2 promotes urothelial cancer outgrowth via cooperation with androgen receptor signaling. Endocrine Connections, 2018, 7, 1397-1408.	0.8	24
122	Steroid Hormone Receptor Signals as Prognosticators for Urothelial Tumor. Disease Markers, 2015, 2015, 1-12.	0.6	23
123	FOXO1 as a tumor suppressor inactivated via AR/ERÎ ² signals in urothelial cells. Endocrine-Related Cancer, 2020, 27, 231-244.	1.6	23
124	Morphological Variety of Intracellular Microcolonies of <i>Legionella</i> Species in Vero Cells. Microbiology and Immunology, 2001, 45, 557-562.	0.7	22
125	Fibroblast ERα promotes bladder cancer invasion via increasing the CCL1 and IL-6 signals in the tumor microenvironment. American Journal of Cancer Research, 2015, 5, 1146-57.	1.4	22
126	Acute and Subacute Toxicity <i>In Vivo</i> of Thermal-Sprayed Silver Containing Hydroxyapatite Coating in Rat Tibia. BioMed Research International, 2014, 2014, 1-8.	0.9	21

#	Article	IF	CITATIONS
127	Loss of DNA mismatch repair proteins in prostate cancer. Medicine (United States), 2020, 99, e20124.	0.4	21
128	Tenascin-C expression in the lymph node pre-metastatic niche in muscle-invasive bladder cancer. British Journal of Cancer, 2021, 125, 1399-1407.	2.9	21
129	Intracellular Multiplication of <i>Legionella pneumophila</i> in <i>Tetrahymena thermophila</i> . Journal of UOEH, 1994, 16, 263-275.	0.3	21
130	High-grade papillary urothelial carcinoma of the urinary tract: a clinicopathologic analysis of a post–World Health Organization/International Society of Urological Pathology classification cohort from a single academic center. Human Pathology, 2012, 43, 115-120.	1.1	20
131	Increased neutrophil-to-lymphocyte ratio is associated with disease-specific mortality in patients with penile cancer. BMC Cancer, 2016, 16, 396.	1.1	20
132	Histopathological distinction of non-invasive and invasive bladder cancers using machine learning approaches. BMC Medical Informatics and Decision Making, 2020, 20, 162.	1.5	20
133	Silodosin inhibits the growth of bladder cancer cells and enhances the cytotoxic activity of cisplatin via ELK1 inactivation. American Journal of Cancer Research, 2015, 5, 2959-68.	1.4	20
134	Suppression of Androgen Receptor Transactivation and Prostate Cancer Cell Growth by Heterogeneous Nuclear Ribonucleoprotein A1 via Interaction with Androgen Receptor Coregulator ARA54. Endocrinology, 2007, 148, 1340-1349.	1.4	19
135	Papillary urothelial neoplasm of low malignant potential of the urinary bladder: clinicopathologic and outcome analysis from a single academic center. Human Pathology, 2011, 42, 1799-1803.	1.1	19
136	The Impact of Frozen Section Analysis During Partial Nephrectomy on Surgical Margin Status and Tumor Recurrence: A Clinicopathologic Study of 433 Cases. Clinical Genitourinary Cancer, 2013, 11, 527-536.	0.9	19
137	Silodosin inhibits prostate cancer cell growth via ELK1 inactivation and enhances the cytotoxic activity of gemcitabine. Prostate, 2016, 76, 744-756.	1.2	19
138	Suppression of ribosomal protein RPS6KB1 by Nexrutine increases sensitivity of prostate tumors to radiation. Cancer Letters, 2018, 433, 232-241.	3.2	19
139	3Â-Acetoxyandrost-1,5-diene-17-ethylene ketal functions as a potent antiandrogen with marginal agonist activity. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 4440-4444.	3.3	17
140	Does androgen deprivation improve treatment outcomes in patients with low-risk and intermediate-risk prostate cancer?. Nature Clinical Practice Oncology, 2005, 2, 236-237.	4.3	17
141	Predicting the mineral composition of ureteral stone using non-contrast computed tomography. Urolithiasis, 2016, 44, 231-239.	1.2	17
142	Androgen Receptor Signaling Reduces Radiosensitivity in Bladder Cancer. Molecular Cancer Therapeutics, 2018, 17, 1566-1574.	1.9	17
143	Pmepa1 induced by RANKLâ€p38 MAPK pathway has a novel role in osteoclastogenesis. Journal of Cellular Physiology, 2018, 233, 3105-3118.	2.0	17
144	Androgen Receptor Signaling Reduces the Efficacy of Bacillus Calmette-Guérin Therapy for Bladder Cancer via Modulating Rab27b-Induced Exocytosis. Molecular Cancer Therapeutics, 2020, 19, 1930-1942.	1.9	17

HIROSHI ΜΙΥΑΜΟΤΟ

#	Article	IF	CITATIONS
145	Sex Hormone Receptor Signaling in Bladder Cancer: A Potential Target for Enhancing the Efficacy of Conventional Non-Surgical Therapy. Cells, 2021, 10, 1169.	1.8	17
146	Expression of receptor activator of nuclear factor kappaÂB ligand in bladder cancer. International Journal of Urology, 2018, 25, 901-902.	0.5	16
147	The Role of Estrogen Receptors in Urothelial Cancer. Frontiers in Endocrinology, 2021, 12, 643870.	1.5	16
148	A unique and common restriction fragment pattern of the nucleotide sequences homologous to the genome of Vf33, a filamentous bacteriophage, in pandemic strains ofVibrio parahaemolyticusO3:K6 O4:K68, and O1:K untypeable. FEMS Microbiology Letters, 2000, 192, 231-236.	0.7	15
149	Lack of an Association between Neutrophil-to-Lymphocyte Ratio and PSA Failure of Prostate Cancer Patients Who Underwent Radical Prostatectomy. BioMed Research International, 2016, 2016, 1-6.	0.9	15
150	The Role of Glucocorticoid Receptor Signaling in Bladder Cancer Progression. Cancers, 2018, 10, 484.	1.7	15
151	2-Methacryloyloxyethyl Phosphorylcholine Polymer Coating Inhibits Bacterial Adhesion and Biofilm Formation on a Suture: An In Vitro and In Vivo Study. BioMed Research International, 2020, 2020, 1-8.	0.9	15
152	Comparative molecular analysis of testicular Leydig cell tumors demonstrates distinct subsets of neoplasms with aggressive histopathologic features. Modern Pathology, 2021, 34, 1935-1946.	2.9	15
153	Bilateral adrenocortical carcinoma showing loss of heterozygosity at the p53 and rb gene loci. Cancer Genetics and Cytogenetics, 1996, 88, 181-183.	1.0	14
154	Mixed Epithelial and Stromal Tumor of the Kidney in a 14-Year-Old Boy. Urologia Internationalis, 2012, 88, 247-248.	0.6	14
155	Percent Gleason pattern 4 in stratifying the prognosis of patients with intermediate-risk prostate cancer. Translational Andrology and Urology, 2018, 7, S484-S489.	0.6	14
156	Attenuation of NAD[P]H:quinone oxidoreductase 1 aggravates prostate cancer and tumor cell plasticity through enhanced TGF12 signaling. Communications Biology, 2020, 3, 12.	2.0	14
157	FOXO1 inactivation induces cisplatin resistance in bladder cancer. Cancer Science, 2020, 111, 3397-3400.	1.7	14
158	The combination of silver-containing hydroxyapatite coating and vancomycin has a synergistic antibacterial effect on methicillin-resistant <i>Staphylococcus aureus</i> biofilm formation. Bone and Joint Research, 2020, 9, 211-218.	1.3	14
159	Identification of steroid derivatives that function as potent antiandrogens. International Journal of Cancer, 2005, 117, 866-872.	2.3	13
160	Moraxella catarrhalis bacteraemia associated with prosthetic vascular graft infection. Journal of Medical Microbiology, 2010, 59, 245-250.	0.7	13
161	Clinical benefits of frozen section assessment during urological surgery: Does it contribute to improving surgical margin status and patient outcomes as previously thought?. International Journal of Urology, 2017, 24, 25-31.	0.5	13
162	Prostate transmembrane protein androgen induced 1 is induced by activation of osteoclasts and regulates bone resorption. FASEB Journal, 2019, 33, 4365-4375.	0.2	13

#	Article	IF	CITATIONS
163	Role of frozen section analysis of testicular/paratesticular fibrous pseudotumours: a five-case experience. Canadian Urological Association Journal, 2011, 5, e47-e51.	0.3	13
164	Investigation of the role of macrophages and endogenous interferon-ÃŽÂ ³ in natural resistance of mice againstLegionella pneumophilainfection. FEMS Microbiology Letters, 1992, 89, 183-192.	0.7	12
165	Temperature Effects on <i>Legionella pneumophila</i> Killing by and Multiplication in Phagocytes of Guinea Pigs. Microbiology and Immunology, 1995, 39, 647-654.	0.7	12
166	<i>Legionella thermalis</i> sp. nov., isolated from hot spring water in Tokyo, Japan. Microbiology and Immunology, 2016, 60, 203-208.	0.7	12
167	NFATc1 Expression as a Prognosticator in Urothelial Carcinoma of the Upper Urinary Tract. Translational Oncology, 2017, 10, 318-323.	1.7	12
168	Androgen Receptor Signaling Induces Cisplatin Resistance via Down-Regulating GULP1 Expression in Bladder Cancer. International Journal of Molecular Sciences, 2021, 22, 10030.	1.8	12
169	TR4 nuclear receptor enhances prostate cancer initiation via altering the stem cell population and EMT signals in the PPARG-deleted prostate cells. Oncoscience, 2015, 2, 142-150.	0.9	12
170	Flow cytometric DNA content analysis in primary lung cancer: Comparison of results from fresh and paraffin-embedded specimens. Journal of Surgical Oncology, 1990, 43, 36-39.	0.8	11
171	Investigation of Legionella Contamination in Bath Water Samples by Culture, Amoebic Co-Culture, and Real-Time Quantitative PCR Methods. International Journal of Environmental Research and Public Health, 2015, 12, 13118-13130.	1.2	11
172	Pretreatment Neutrophil-to-Lymphocyte Ratio Can Predict the Prognosis in Bladder Cancer Patients Who Receive Gemcitabine and Nedaplatin Therapy. BioMed Research International, 2016, 2016, 1-5.	0.9	11
173	Oxidative stress marker 8-hydroxyguanosine is more highly expressed in prostate cancer than in benign prostatic hyperplasia. Molecular and Clinical Oncology, 2018, 9, 302-304.	0.4	11
174	Identification of BXDC2 as a Key Downstream Effector of the Androgen Receptor in Modulating Cisplatin Sensitivity in Bladder Cancer. Cancers, 2021, 13, 975.	1.7	11
175	ELK1 promotes urothelial tumorigenesis in the presence of an activated androgen receptor. American Journal of Cancer Research, 2018, 8, 2325-2336.	1.4	11
176	Transurethral Resection Specimens of the Bladder: Outcome of Invasive Urothelial Cancer Involving Muscle Bundles Indeterminate Between Muscularis Mucosae and Muscularis Propria. Urology, 2010, 76, 600-602.	0.5	10
177	Developing a preoperative predictive model for ureteral length for ureteral stent insertion. BMC Urology, 2016, 16, 70.	0.6	10
178	Deficiency of stressâ€associated gene <i>Nupr1</i> increases bone volume by attenuating differentiation of osteoblasts. FASEB Journal, 2019, 33, 8836-8852.	0.2	10
179	Distribution of androgen receptor expression in the urinary bladder. International Journal of Urology, 2019, 26, 305-306.	0.5	10
180	The Role of Steroid Hormone Receptors in Urothelial Tumorigenesis. Cancers, 2020, 12, 2155.	1.7	10

#	Article	IF	CITATIONS
181	Rapid detection method of carbapenemase-producing Enterobacteriaceae by MALDI-TOF MS with imipenem/cilastatin (KB) disc and zinc sulfate solution. Journal of Infection and Chemotherapy, 2021, 27, 205-210.	0.8	10
182	Changes in carotid blood flow and electrocardiogram in humans during and after walking on a treadmill. European Journal of Applied Physiology and Occupational Physiology, 1993, 67, 486-491.	1.2	9
183	Pulmonary metastases from uterine neoplasms after long tumour-free interval: four cases and review of the literature. Pathology, 2009, 41, 234-241.	0.3	9
184	Expression of Phospho-ELK1 and Its Prognostic Significance in Urothelial Carcinoma of the Upper Urinary Tract. International Journal of Molecular Sciences, 2018, 19, 777.	1.8	9
185	Role of glucocorticoid signaling in urothelial tumorigenesis: Inhibition by prednisone presumably through inducing glucocorticoid receptor transrepression. Molecular Carcinogenesis, 2019, 58, 2297-2305.	1.3	9
186	Activation of Glucocorticoid Receptor Inhibits the Stem-Like Properties of Bladder Cancer via Inactivating the β-Catenin Pathway. Frontiers in Oncology, 2020, 10, 1332.	1.3	9
187	Why has the prognosis for muscle-invasive bladder cancer not significantly improved after decades of therapeutic advancements?. Expert Review of Anticancer Therapy, 2020, 20, 229-231.	1.1	9
188	Comparison of two types of matrix-assisted laser desorption/ionization time-of-flight mass spectrometer for the identification and typing of Clostridium difficile. Journal of Medical Microbiology, 2015, 64, 1144-1150.	0.7	9
189	Enzalutamide as an androgen receptor inhibitor prevents urothelial tumorigenesis. American Journal of Cancer Research, 2017, 7, 2041-2050.	1.4	9
190	The Differential Effects of Anti-Diabetic Thiazolidinedione on Prostate Cancer Progression Are Linked to the TR4 Nuclear Receptor Expression Status. Neoplasia, 2015, 17, 339-347.	2.3	8
191	STAT3 expression is a prognostic marker in upper urinary tract urothelial carcinoma. PLoS ONE, 2018, 13, e0201256.	1.1	8
192	Evidence for 2-Methoxyestradiol-Mediated Inhibition of Receptor Tyrosine Kinase RON in the Management of Prostate Cancer. International Journal of Molecular Sciences, 2021, 22, 1852.	1.8	8
193	The Clinical Significance of Perineural Invasion by Prostate Cancer on Needle Core Biopsy: Involvement of Single Versus Multiple Sextant Sites. Archives of Pathology and Laboratory Medicine, 2022, 146, 1252-1257.	1.2	8
194	Androgen Receptor Antagonists in the Treatment of Prostate Cancer. Clinical Immunology, Endocrine and Metabolic Drugs, 2014, 1, 11-19.	0.3	7
195	Bone management in Japanese patients with prostate cancer: hormonal therapy leads to an increase in the FRAX score. BMC Urology, 2016, 16, 32.	0.6	7
196	The Neutrophil-to-Lymphocyte Ratio before Repeat Prostate Needle Biopsy for Predicting Prostate Cancer. Urologia Internationalis, 2016, 96, 123-124.	0.6	7
197	Antibacterial Activity of Agâ€Hydroxyapatite Coating Against Hematogenous Infection by Methicillinâ€Resistant <i>Staphylococcus aureus</i> in the Rat Femur. Journal of Orthopaedic Research, 2019, 37, 2655-2660.	1.2	7
198	The impact of perivesical lymph node metastasis on clinical outcomes of bladder cancer patients undergoing radical cystectomy. BMC Urology, 2019, 19, 77.	0.6	7

#	Article	IF	CITATIONS
199	Discolored Ureteral Stents: Findings in Urinalysis and Urine Culture. PLoS ONE, 2015, 10, e0122984.	1.1	7
200	Semenogelin I promotes prostate cancer cell growth via functioning as an androgen receptor coactivator and protecting against zinc cytotoxicity. American Journal of Cancer Research, 2015, 5, 738-47.	1.4	7
201	Dependence on exercise intensity of changes in electrolyte secretion from the skin sampled by a simple method. European Journal of Applied Physiology and Occupational Physiology, 1990, 60, 407-411.	1.2	6
202	Kinetic study on the effects of intracellular K++ and Na++ on Na++, K++, Cl+? cotransport of HeLa cells by Rb++ influx determination. Journal of Membrane Biology, 1993, 132, 115-24.	1.0	6
203	Early versus late hormonal therapy for prostate cancer. Current Urology Reports, 2004, 5, 188-196.	1.0	6
204	RANK/RANKL expression in prostate cancer. International Journal of Surgery Case Reports, 2017, 30, 106-107.	0.2	6
205	Practice patterns related to prostate cancer grading: results of a 2019 Genitourinary Pathology Society clinician survey. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 295.e1-295.e8.	0.8	6
206	HL-A AND ITS CLINICAL APPLICATION. Keio Journal of Medicine, 1972, 21, 159-169.	0.5	6
207	Secondary malignancy after urologic reconstruction procedures: a multi-institutional case series. Human Pathology, 2022, 119, 69-78.	1.1	6
208	Arrest of cell cycle progression of HeLa cells in the early G1 phase in K+-depleted conditions and its recovery upon addition of insulin and LDL. Journal of Cellular Biochemistry, 1993, 53, 13-20.	1.2	5
209	Low-molecular-weight protein tyrosine phosphatase expression as a prognostic factor for men with metastatic hormone-naÃ`ve prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 607.e9-607.e14.	0.8	5
210	The interaction between androgen receptor and semenogelin I: a synthetic LxxLL peptide antagonist inhibits the growth of prostate cancer cells. British Journal of Cancer, 2018, 118, 416-420.	2.9	5
211	The Impact of Routine Frozen Section Assessment During Penectomy on Surgical Margin Status and Long-Term Oncologic Outcomes. Pathology and Oncology Research, 2018, 24, 947-950.	0.9	5
212	PMEPA1 and NEDD4 control the proton production of osteoclasts by regulating vesicular trafficking. FASEB Journal, 2021, 35, e21281.	0.2	5
213	Intraoperative pathology consultation during urological surgery: Impact on final margin status and pitfalls of frozen section diagnosis. Pathology International, 2021, 71, 567-580.	0.6	5
214	Estrogen receptor-β signaling induces cisplatin resistance in bladder cancer. American Journal of Cancer Research, 2020, 10, 2523-2534.	1.4	5
215	The Clinical Impact of pT3a Lesions in Patients With pT3b Prostate Cancer Undergoing Radical Prostatectomy. Archives of Pathology and Laboratory Medicine, 2022, 146, 619-625.	1.2	5
216	Clinical significance of perineural invasion by prostate cancer on magnetic resonance imaging–targeted biopsy. Human Pathology, 2022, 121, 65-72.	1.1	5

#	Article	IF	CITATIONS
217	Retroperitoneal tumor eleven years after initial treatment of testicular cancer. Urology, 1994, 43, 116-117.	0.5	4
218	Fate of <i>Legionella pneumophila</i> in Macrophages of C57BL/6 Chronic Granulomatous Disease Mice. Microbiology and Immunology, 2001, 45, 539-541.	0.7	4
219	Chronic inflammation on initial benign prostate biopsy is a negative predictor of subsequent cancer detection. Pathology International, 2012, 62, 774-776.	0.6	4
220	Histopathologic features of atypical glands on prostate biopsy: Nucleolar size is a predictor of subsequent detection of prostatic adenocarcinoma. Prostate, 2013, 73, 376-381.	1.2	4
221	MP83-20 ENZALUTAMIDE AS AN ANDROGEN RECEPTOR INHIBITOR PREVENTS UROTHELIAL TUMORIGENESIS. Journal of Urology, 2016, 195, .	0.2	4
222	Renal Papillary and Calyceal Lesions at CT Urography: Genitourinary Imaging. Radiographics, 2017, 37, 358-359.	1.4	4
223	Forkhead box O1 as an indicator of prognosis is inactivated in urothelial carcinoma of the upper urinary tract. Oncology Letters, 2018, 17, 482-487.	0.8	4
224	Continuous versus discontinuous tumor involvement: A dilemma in prostate biopsy quantitation. Prostate, 2018, 78, 1166-1171.	1.2	4
225	Preference for enzalutamide capsules versus tablet pills in patients with prostate cancer. International Journal of Urology, 2019, 26, 1161-1162.	0.5	4
226	Impact of Vasectomy on the Development and Progression of Prostate Cancer: Preclinical Evidence. Cancers, 2020, 12, 2295.	1.7	4
227	Time-dependent efficacy of combination of silver-containing hydroxyapatite coating and vancomycin on methicillin-resistant Staphylococcus aureusAbiofilm formation in vitro. BMC Research Notes, 2021, 14, 81.	0.6	4
228	Testicular Germ-Cell Tumors with Spermatic Cord Involvement: A Retrospective International Multi-Institutional Experience. Modern Pathology, 2021, , .	2.9	4
229	The role of adipocytokines and their receptors in bladder cancer: expression of adiponectin or leptin is an independent prognosticator. American Journal of Translational Research (discontinued), 2020, 12, 3033-3045.	0.0	4
230	The Clinical Impact of Unilateral Versus Bilateral Invasion Into the Seminal Vesicle in Patients With Prostate Cancer Undergoing Radical Prostatectomy. Archives of Pathology and Laboratory Medicine, 2022, 146, 855-861.	1.2	4
231	Stimulating effects of insulin and low-density lipoprotein on cell growth and macromolecular syntheses of HeLa cells cultured in K+-depleted medium. Journal of Cellular Physiology, 1990, 144, 254-261.	2.0	3
232	Eppin Expression in Prostate Cancer. European Urology, 2011, 59, 1071-1072.	0.9	3
233	Ramelteon combined with an α1-blocker decreases nocturia in men with benign prostatic hyperplasia. BMC Urology, 2013, 13, 30.	0.6	3
234	Intravesical Bacillus Calmette-GuerinTherapy for Bladder Cancer: Molecular Mechanisms of Action. Clinical Immunology, Endocrine and Metabolic Drugs, 2016, 3, 31-38.	0.3	3

#	Article	IF	CITATIONS
235	Complete Penile Disassembly for Repair of Epispadias Causes Erectile Tissue Alteration Through Transforming Growth Factor Beta 1 Overexpression in a Rabbit Model. Urology, 2018, 111, 151-156.	0.5	3
236	5α-Reductase Inhibitors Do Not Prevent the Development and Progression of Urothelial Cancer: In Vitro Evidence. Bladder Cancer, 2020, 6, 481-488.	0.2	3
237	Programmed cell deathâ€ligand 1 expression in different molecular subtypes of upper tract urothelial carcinoma. International Journal of Urology, 2022, 29, 89-90.	0.5	3
238	Differential Roles of Androgen Receptor in Prostate Development and Cancer Progression. , 2009, , 73-89.		3
239	Limited Adenocarcinoma of the Prostate on Needle Core Biopsy. Archives of Pathology and Laboratory Medicine, 2022, 146, 469-477.	1.2	3
240	Identification of a Vitamin-D Receptor Antagonist, MeTC7, which Inhibits the Growth of Xenograft and Transgenic Tumors <i>In Vivo</i> . Journal of Medicinal Chemistry, 2022, 65, 6039-6055.	2.9	3
241	The Clinical Impact of Comedonecrosis Within Intraductal Carcinoma of the Prostate. Archives of Pathology and Laboratory Medicine, 2023, 147, 94-99.	1.2	3
242	The role of periprostatic and periseminal vesicle lymph node metastasis in the staging and prognosis of prostate cancer. Histopathology, 2012, 60, 1009-1010.	1.6	2
243	MP31-08 SEMENOGELIN I PROMOTES PROSTATE CANCER CELL GROWTH VIA FUNCTIONING AS AN ANDROGEN RECEPTOR COACTIVATOR AND PROTECTING AGAINST ZINC CYTOTOXICITY. Journal of Urology, 2014, 191, .	0.2	2
244	Uridine 5'diphosphoâ€glucuronosyltransferase 1A expression as an independent prognosticator in urothelial carcinoma of the upper urinary tract. International Journal of Urology, 2018, 25, 429-435.	0.5	2
245	Is Tubulocystic Renal Cell Carcinoma Real?. Journal of Molecular Diagnostics, 2018, 20, 28-30.	1.2	2
246	Sex Hormone Receptor Signals in Human Malignancies. International Journal of Molecular Sciences, 2019, 20, 2677.	1.8	2
247	Clinical implication of the mammalian target of rapamycin pathway in upper tract urothelial carcinoma with negative GATA binding proteinÂ3 expression. International Journal of Urology, 2019, 26, 678-679.	0.5	2
248	Cribriform pattern and perineural invasion on MR/US fusion biopsy predict failure of selection criteria for prostatic hemigland ablation. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 38.e1-38.e8.	0.8	2
249	MP54-17 GLUCOCORTICOID RECEPTOR AND FOXO1 EXPRESSION IN BLADDER CANCER AS AN INDEPENDENT PROGNOSTICATOR. Journal of Urology, 2018, 199, .	0.2	2
250	The impact of routine frozen section analysis during partial cystectomy for bladder cancer on surgical margin status and long-term oncologic outcome. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 933.e1-933.e6.	0.8	2
251	Bioâ€Psychoâ€Socioâ€Ecological Risk Factors for <i>Legionella</i> Infection among Japanese 24â€Hour Hot Water Bath Users and Nonâ€Users. Journal of Occupational Health, 2000, 42, 205-212.	1.0	2
252	The prognostic role of steroid hormone receptor signaling pathways in urothelial carcinoma. Translational Cancer Research, 2020, 9, 6596-6608.	0.4	2

#	Article	IF	CITATIONS
253	BRONCHIAL SMEAR IN LUNG TRANSPLANTATION. Keio Journal of Medicine, 1972, 21, 49-56.	0.5	2
254	The Role of Mineralocorticoid Receptor Signaling in Genitourinary Cancers. Nuclear Receptor Research, 2019, 6, .	2.5	2
255	Compound A inhibits urothelial tumorigenesis via both the androgen receptor and glucocorticoid receptor signaling pathways. American Journal of Translational Research (discontinued), 2020, 12, 1779-1788.	0.0	2
256	Effects of α-adrenergic receptor antagonists on the development and progression of urothelial cancer. American Journal of Cancer Research, 2020, 10, 4386-4398.	1.4	2
257	Radical prostatectomy findings and oncologic outcomes in patients with prostate cancer detected on systematic sextant biopsy only, MRI-targeted biopsy only, or both. Urologic Oncology: Seminars and Original Investigations, 2022, , .	0.8	2
258	Phenazine methosulfate stimulation of ouabain-sensitive Rb+ uptake by HeLa cells: Effects of respiratory inhibitors, anaerobiosis, and ascorbate. Journal of Cellular Biochemistry, 1985, 28, 273-280.	1.2	1
259	A 1â€Year Followâ€Up Study of Antiâ€ <i>Legionella</i> Antibodies in Users of Japanese 24â€Hour Hot Water Baths. Journal of Occupational Health, 2001, 43, 46-49.	1.0	1
260	Clinicopathologic Features of Prostate Cancer in Patients Diagnosed by Age 45 Who Underwent Radical Prostatectomy. European Urology, 2012, 62, 354-355.	0.9	1
261	Authors' Response to Chew and Lange. Journal of Endourology, 2013, 27, 507-507.	1.1	1
262	Evaluation of the structure of Ag in thermal sprayed Ag-containing hydroxyapatite coatings. Journal of the Ceramic Society of Japan, 2015, 123, 667-671.	0.5	1
263	Expression of PD-L1 and CTLA-4 in female urethral carcinoma. IJU Case Reports, 2019, 2, 23-26.	0.1	1
264	Successful treatment with sorafenib for sunitinibâ€refractory metastatic papillary renal cell carcinoma: Potential impact of Raf overexpression on predicting the efficacy of sorafenib. IJU Case Reports, 2019, 2, 43-46.	0.1	1
265	Prediction of Time to Castration-Resistant Prostate Cancer Using Low-Molecular-Weight Protein Tyrosine Phosphatase Expression for Men with Metastatic Hormone-NaÃ ⁻ ve Prostate Cancer. Urologia Internationalis, 2019, 102, 37-42.	0.6	1
266	Androgen Receptor in Prostate Cancer Progression. , 2008, , 129-146.		1
267	ZKSCAN3 expression in urothelial carcinoma of the upper urinary tract and its impact on patient outcomes. Integrative Cancer Science and Therapeutics, 2017, 4, .	0.1	1
268	An auscultatory recording method for blood pressure measurement during exercise The Japanese Journal of Physiology, 1987, 37, 757-760.	0.9	1
269	MP24-15â€∱MR/US FUSION TARGETED BIOPSY FAILED TO DETECT PROSTATE CANCER: ROLE OF CONFIRMMDXÂ AS AN ADJUNCT. Journal of Urology, 2019, 201, .	0.2	1
270	Conditional reprogramming technology: a new tool for personalized medicine in bladder cancer?. Translational Cancer Research, 2019, 8, S636-S638.	0.4	1

#	Article	IF	CITATIONS
271	Pulse granuloma in the distal ureter, a malignancy mimicker. Pathology International, 2022, 72, 318-319.	0.6	1
272	Early versus late hormonal therapy for prostate cancer. Current Prostate Reports, 2004, 2, 60-68.	0.1	0
273	HORMONAL THERAPY FOR PROSTATE CANCER: CLINICAL AND EXPERIMENTAL EVIDENCE. , 2005, , 1-32.		0
274	Erratum for Characteristics of Bacterial Species in Positive Blood Cultures among Hospitalized Patients in Three Wards in the Department of Internal Medicine: Retrospective Chart Review 1999-2008. Internal Medicine, 2012, 51, 3315-3315.	0.3	0
275	Urine-Based Assays Complementing Cytologic Examination in the Detection of Urothelial Neoplasm. , 2012, , 109-121.		0
276	Role of frozen section analysis of testicular/paratesticular fibrous pseudotumours: a five-case experience. Canadian Urological Association Journal, 2013, 5, 47.	0.3	0
277	Intraoperative Consultation for Renal Masses: Challenges and Implications for Treatment. , 2015, , 401-405.		0
278	MP71-04 GATA3 IMMUNOHISTOCHEMISTRY IN UROTHELIAL CARCINOMA OF THE UPPER URINARY TRACT AS A UROTHELIAL MARKER AS WELL AS A PROGNOSTICATOR. Journal of Urology, 2017, 197, .	0.2	0
279	MP87-15 INHIBITION OF RPS6KB1 AS A POTENTIAL ADJUVANT FOR PROSTATE CANCER RADIATION THERAPY. Journal of Urology, 2017, 197, .	0.2	0
280	Lack of an association between the aPKCλ/ι expression in prostate cancer and the patient outcomes. International Journal of Surgery Case Reports, 2017, 37, 180-182.	0.2	0
281	PD49-08 THE IMPACT OF ROUTINE FROZEN SECTION ANALYSIS DURING PENECTOMY ON SURGICAL MARGIN STATUS AND LONG-TERM ONCOLOGIC OUTCOMES. Journal of Urology, 2017, 197, .	0.2	0
282	MP88-06 NUCLEAR FACTOR (NF)-κB SIGNALS PROMOTE UROTHELIAL TUMORIGENESIS THROUGH THE ANDROGEN RECEPTOR (AR) PATHWAY. Journal of Urology, 2017, 197, .	0.2	0
283	MP48-13 LOSS OF FORKHEAD BOX PROTEIN O1 (FOXO1) IN BLADDER CANCER INDUCES TUMOR PROGRESSION AS WELL AS CHEMORESISTANCE. Journal of Urology, 2017, 197, .	0.2	Ο
284	MP71-08 EXPRESSION OF TRANSCRIPTION FACTORS, ELK1, FOXO1, NFATC1, AND ZKSCAN3, IN UROTHELIAL CARCINOMA OF THE UPPER URINARY TRACT AS PROGNOSTICATORS. Journal of Urology, 2017, 197, .	0.2	0
285	MP88-07 ANDROGEN RECEPTOR ACTIVITY MODULATES RADIOSENSITIVITY IN BLADDER CANCER CELLS. Journal of Urology, 2017, 197, .	0.2	Ο
286	MP88-08 ESTROGEN RECEPTOR (ER)-Î ² SIGNALS INDUCE UROTHELIAL TUMORIGENESIS VIA DOWN-REGULATION OF A POTENTIAL TUMOR SUPPRESSOR FORKHEAD BOX PROTEIN O1 (FOXO1). Journal of Urology, 2017, 197, .	0.2	0
287	PD11-10 IMPACT OF GLEASON PATTERN 4 CRIBRIFORM ARCHITECTURE ON PROSTATE CANCER DETECTION USING MULTIPARAMETRIC MRI. Journal of Urology, 2017, 197, .	0.2	0
288	MP53-07 PREDICTORS OF IPSILATERAL EXTRAPROSTATIC EXTENSION ON RADICAL PROSTATECTOMY USING 3-TESLA MULTIPARAMETRIC MRI AND CONTEMPORARY PATHOLOGIC FEATURES. Journal of Urology, 2018, 199, .	0.2	0

#	Article	IF	CITATIONS
289	Novel 1.3 Mb germline duplication in chromosome 8q21.11 by microarray comparative genomic hybridizationAplus single nucleotide polymorphism analysis in an adult patient with pancytopenia and urinary bladder complications. Clinical Case Reports (discontinued), 2018, 6, 1947-1952.	0.2	0
290	Prostatic adenocarcinoma with aberrant diffuse expression of high molecular weight cytokeratin. Pathology, 2018, 50, 787-789.	0.3	0
291	MP54-08 PROSTAGLANDIN RECEPTORS INDUCE UROTHELIAL TUMOURIGENESIS AS WELL AS BLADDER CANCER PROGRESSION AND CISPLATIN RESISTANCE PRESUMABLY VIA MODULATING PTEN EXPRESSION. Journal of Urology, 2018, 199, .	0.2	0
292	MP58-03 ANDROGEN RECEPTOR SIGNALING REDUCES RADIOSENSITIVITY IN BLADDER CANCER. Journal of Urology, 2018, 199, .	0.2	0
293	Implants in the distal radius unlikely to induce a new niche for microbiomes. Apmis, 2020, 128, 603-604.	0.9	0
294	Abstract PO-085: Therapeutic targeting of RPS6KB1/SQSTM1 axis to prevent biochemical recurrence. , 2021, , .		0
295	Primary adrenal melanoma: A case report and review of the literature. Journal of Clinical Urology, 2024, 17, 53-56.	0.1	0
296	Interaction of Cell Cycle Regulatory Proteins with the Androgen Receptor. , 2002, , 223-238.		0
297	PROLONGED SURVIVAL OF RAT SKIN ALLOGRAFTS TREATED BY PROLONGED HYPOTHERMIA. Keio Journal of Medicine, 1969, 18, 71-79.	0.5	0
298	MEASUREMENT OF CARTILAGE THICKNESS ON THE ARTICULAR FACE OF THE HUMAN PATELLA AND MOVEMENT OF THE PATELLA DURING FLEXION OF THE KNEE. Japanese Journal of Physical Fitness and Sports Medicine, 1991, 40, 102-110.	0.0	0
299	COMPARISONS OF LEFT VENTRICULAR SYSTOLIC AND DIASTOLIC TIMES IN EXERCISE BETWEEN TRAINED AND UNTRAINED MEN. Japanese Journal of Physical Fitness and Sports Medicine, 1991, 40, 145-155.	0.0	0
300	Intraoperative Consultation for Bladder Tumors: Challenges and Implications for Treatment. , 2015, , 247-251.		0
301	Androgen deprivation therapy to prevent bladder cancer recurrence Journal of Clinical Oncology, 2015, 33, 329-329.	0.8	0
302	The neutrophil-to-lymphocyte ratio is an effective prognostic marker in localized upper urinary tract urothelial carcinoma treated with nephroureterectomy. Integrative Cancer Science and Therapeutics, 2017, 4, .	0.1	0
303	Renal cell carcinoma with osseous metaplasia: A case report and literature review. Integrative Cancer Science and Therapeutics, 2017, 4, .	0.1	0
304	DeltaNp63 expression is a biomarker to predict survival after recurrence of upper urinary tract urothelial carcinoma. Integrative Cancer Science and Therapeutics, 2018, 5, .	0.1	0
305	Evaluation of ability of OR51T1 expression to predict primary hormone therapy efficacy among men with hormone-naà ve metastatic prostate cancer Journal of Clinical Oncology, 2018, 36, 317-317.	0.8	0
306	MP30-08 PERINEURAL INVASION PREDICTS FAILURE OF MR/US FUSION BIOPSY-BASED SELECTION CRITERIA FOR HEMIABLATIVE FOCAL THERAPY IN PATIENTS WITH INTERMEDIATE-RISK PROSTATE CANCER. Journal of Urology, 2018, 199, .	0.2	0

#	Article	IF	CITATIONS
307	MP18-10 STAT3 EXPRESSION IS A PROGNOSTIC MARKER IN UPPER URINARY TRACT UROTHELIAL CARCINOMA. Journal of Urology, 2018, 199, .	0.2	0
308	PD65-08 SEMENOGELIN I AS AN ANDROGEN RECEPTOR CO-ACTIVATOR: A SYNTHETIC LXXLL PEPTIDE ANTAGONIST INHIBITS THE GROWTH OF PROSTATE CANCER CELLS. Journal of Urology, 2018, 199, .	0.2	0
309	Editorial comments to the articles published in Issues 1-3 of Volume 6. Integrative Cancer Science and Therapeutics, 2019, 6, .	0.1	Ο
310	PD17-12 FREQUENCY OF DOWNGRADING FROM MR/US FUSION BIOPSY TO RADICAL PROSTATECTOMY BASI ON ISUP 2014 GRADING MODIFICATIONS. Journal of Urology, 2019, 201, .	ED 0.2	0
311	MP51-10â€ f ATF2 PROMOTES UROTHELIAL TUMORIGENESIS AND TUMOR PROGRESSION VIA THE ANDROGEN RECEPTOR PATHWAY. Journal of Urology, 2019, 201, .	0.2	0
312	MP57-08 ANDROGEN RECEPTOR SIGNALING REDUCES DIRECT CYTOTOXICITY OF BACILLUS CALMETTE-Gué (BCG) IN BLADDER CANCER CELLS VIA MODULATING RAB27B. Journal of Urology, 2019, 201, .	RIN 0.2	0
313	Abstract 5082: SIRT1 functions as a double-edged sword in prostate cancer. , 2019, , .		Ο
314	PD47-08 URINARY EXOSOME CYTOKINE LEVELS CORRELATE WITH PELVIC LYMPH NODE INFLAMMATION. Journal of Urology, 2020, 203, .	0.2	0
315	Abstract 2071: Identification of FOXO1 as a tumor suppressor modulated by androgen receptor/estrogen receptor-l²signals: Implications for bladder cancer promotion and chemoresistance. , 2020, , .		0
316	MP17-02 TENASCIN C EXPRESSION IN BENIGN PELVIC LYMPH NODES CORRELATES WITH METASTATIC STATU AND SURVIVAL. Journal of Urology, 2020, 203, .	S _{0.2}	0
317	MP17-11 IDENTIFICATION OF FOXO1 AS A TUMOR SUPPRESSOR MODULATED BY ANDROGEN RECEPTOR/ESTROGEN RECEPTOR-β SIGNALS: IMPLICATIONS FOR BLADDER CANCER PROMOTION AND CHEMORESISTANCE. Journal of Urology, 2020, 203, .	0.2	Ο
318	MP53-19 ANDROGEN DEPRIVATION THERAPY THROUGH THE PERI-RADIATION PERIOD REDUCES THE RISK OF BLADDER HEMORRHAGE IN PROSTATE CANCER PATIENTS UNDERGOING EXTERNAL BEAM RADIOTHERAPY. Journal of Urology, 2020, 203, .	0.2	0
319	Abstract 3943: Inhibition of ribosomal protein RPS6KB1 as a strategy to improve conventional therapy for prostate cancer. , 2019, , .		0
320	Correlation of Strain Classification with IR Biotyper and Molecular Epidemiological Method of RinshŕBiseibutsu Jinsoku Shindan Kenkyūkai Shi = JARMAM: Journal of the Association for Rapid Method and Automation in Microbiology, 2021, 31, 29-40.	0.0	0